Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Prostatic Cancer: early-phase trial registry

2 of 5 indexed Prostatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Prostatic Cancer: 5 US clinical trials tracked, 2 recruiting.

Prostatic Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.

Enrollment posture brief

Registry condition prostatic-cancer

OPEN 2 | RECR 40% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Prostatic Cancer (this)40%
Open-enrollment share among volume-matched conditions near Prostatic Cancer

Prostatic Cancer lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostatic Cancer is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Prostatic Cancer research.

    National Cancer Institute (NCI) accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostatic Cancer enrolment sits around 307 participants.

    Median target enrolment is 307 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Prostatic Cancer splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Prostatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CyberKnife Stereotactic Radiosurgery - Intermediate Risk Radiation
1 trials
CyberKnife Stereotactic Radiosurgery - Low Risk Radiation
1 trials
18F-DCFPyL Drug
1 trials
18F-NaF Drug
1 trials
Stereostatic Body Radiation Therapy Radiation
1 trials
High Dose Brachytherapy Radiation
1 trials
18F-FDG Drug
1 trials

US sites by state

Facility locations filed on Prostatic Cancer trials. A trial with sites in several states counts in each.

North Carolina 2 trials
Maryland 2 trials
Texas 1 trials
Tennessee 1 trials
Oklahoma 1 trials
Nevada 1 trials
New Jersey 1 trials
Nebraska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostatic Cancer page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Cancer condition card totals 5 registered trials; most-linked intervention CyberKnife Stereotactic Radiosurgery - Intermediate Risk; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.